Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from Intellia Therapeutics’s reported figures.
The source filing: Intellia Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-337952
FAQ
- What is Intellia Therapeutics's EBIT?
- Intellia Therapeutics (NTLA) reported EBIT of -$112.76M in Q2 2026.
- How has Intellia Therapeutics's EBIT changed year-over-year?
- Intellia Therapeutics's EBIT decreased by 2.5% year-over-year, from -$110M to -$112.76M.
- What is the long-term trend for Intellia Therapeutics's EBIT?
- Over 4 years (2021 to 2025), Intellia Therapeutics's EBIT has grown at a 13.3% compound annual growth rate (CAGR), from -$267.85M to -$440.99M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Intellia Therapeutics's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude